Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Viatris (VTRS) completed its acquisition of Pacira BioSciences (PCRX), making the non-opioid pain management company a wholly owned subsidiary. The transaction, first announced October 8, 2026, pays $36.50 per share in cash, net of applicable withholding taxes and without interest. Approximately 32,929,780 shares, representing approximately 66.46% of outstanding Pacira shares, were validly tendered and not withdrawn. All tender-offer conditions were satisfied or waived on November 17, 2026.
The subsequent merger required no Pacira shareholder vote. Untendered shares were converted into the right to receive the same offer price, and Pacira shares will be delisted from the Nasdaq Global Select Market. Viatris expects the acquisition to contribute $90 million to $100 million in total revenues from November 17 through December 31, 2026.
Ingram Micro Holding (NYSE: INGM) will join the S&P SmallCap 600 before trading opens on November 17, 2026. It will replace Pacira BioSciences (NASD: PCRX), with Ingram classified in Information Technology and Pacira in Health Care. S&P 500 constituent Viatris (NASD: VTRS) is acquiring Pacira in a deal expected to close soon, pending final closing conditions.
Viatris (Nasdaq: VTRS) reported third-quarter 2026 revenue of $3.75 billion, essentially flat compared with the same quarter a year earlier. The GAAP net loss widened to $325.3 million from $128.2 million, while adjusted earnings per share rose 6% to $0.71. Operating cash flow increased 21% to $899.4 million.
The company raised its 2026 guidance midpoints, targeting revenue of $14.8 billion and adjusted earnings per share of $2.60, excluding any Pacira contribution. Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, with closing expected by the end of November 2026.
RYZUMVI received U.S. approval for presbyopia, and WAKIX received Japanese approvals. Viatris suspended manufacturing at its Nashik facility in October. Supply constraints reduced third-quarter revenue by approximately $100 million; the company anticipates approximately the same fourth-quarter impact.
Viatris (VTRS) has commenced a tender offer through its wholly owned subsidiary to acquire Pacira BioSciences (PCRX) for $36.50 per share. The cash payment is net of applicable withholding taxes and without interest. The offer follows the Oct. 8, 2026 merger agreement.
The offer and withdrawal rights expire one minute following 11:59 p.m. Eastern Time on Nov. 16, 2026, unless extended or earlier terminated. Pacira's board unanimously recommends tendering. Completion requires tendered shares plus purchaser-affiliate holdings to represent at least one share more than 50% of outstanding shares, expiration or termination of the applicable antitrust waiting period, and no prohibiting legal restraint. There is no financing condition. Following completion, Pacira would become a wholly owned Viatris subsidiary through a merger requiring no Pacira stockholder vote.
Pacira BioSciences (PCRX) agreed to an acquisition by Viatris (VTRS) for $36.50 per share in cash, through a tender offer.
The agreement values Pacira's equity at $1.65 billion. A second-step merger would acquire shares not tendered for the same consideration. Both boards unanimously approved the transaction, and Pacira's board recommends tendering shares. Closing is expected by the end of 2026, subject to a majority of outstanding shares being tendered and expiration of the applicable regulatory waiting period.
Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA, an adjusted earnings measure before interest, taxes, depreciation and amortization, in the twelve months ended June 30, 2026. Its marketed medicines include EXPAREL and ZILRETTA. Viatris expects to expand their reach across selected international markets.
Pacira BioSciences (PCRX) and Caregiver Action Network announced survey findings on family caregivers’ preparation for postsurgical pain management at home. The Ready, Set, Recover initiative gathered 202 caregiver responses, supplemented by an August 2026 roundtable with 10 caregivers and three individual interviews.
Among respondents, 78% agreed caregivers are often expected to manage pain at home without sufficient information, and 76% expressed concern about managing care during the initial days after surgery. Before surgery, 38% received very little or no information about pain management options. A detailed plan covering medications, timing and side effects was requested by 72%; another 72% said more information would have made them very or somewhat likely to consider or request an alternative. The results are not intended to represent all U.S. family caregivers.
Pacira BioSciences (PCRX) signed an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL in the European Union and United Kingdom. Pacira will manufacture the postsurgical pain treatment and receive an undisclosed upfront payment, a supply price, and royalties on Molteni’s future commercial sales in licensed territories. Molteni will handle regulatory, market access, and commercialization activities.
Molteni plans sequential launches beginning with Italy, Germany, Austria, and Poland, with the first commercial sale expected in 2027, and will pursue Swiss approval. Separately, Pacira granted two new employees options for 3,600 shares at $25.21 per share and restricted stock units for 4,200 shares on October 2, 2026.
Pacira BioSciences (PCRX) granted equity inducement awards on September 2, 2026 to five new employees under its Amended and Restated 2014 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards were approved by the Board’s People & Compensation Committee without stockholder approval.
Three employees received stock options covering an aggregate 8,900 shares of common stock with a 10-year term, a four-year vesting schedule, and an exercise price of $26.58 per share, equal to the September 2, 2026 Nasdaq Global Select Market closing price. Five employees received restricted stock units for an aggregate 14,000 shares, vesting in four annual equal installments beginning September 1, 2027. All vesting is subject to continued employment and award agreements.
Pacira BioSciences (NASDAQ:PCRX) reported publication of positive two-year Phase 1 data for PCRX-201, its investigational locally administered gene therapy for moderate-to-severe knee osteoarthritis, in Annals of the Rheumatic Diseases. A single intra-articular knee injection of PCRX-201 was well tolerated over 104 weeks.
The open-label Phase 1 trial enrolled 72 adults aged 30–80 years in two parts across low, middle, and high doses, with Part 2 adding methylprednisolone pretreatment. Exploratory outcome measures showed improvements in pain, stiffness, and function across all dose cohorts among participants who remained in the study. Glucocorticoid pretreatment was associated with a lower rate of joint effusion and greater clinical improvement and has been incorporated into Pacira’s ongoing Phase 2 ASCEND trial, which has initiated Part B enrollment and targets a first topline readout by year-end 2026.
Pacira BioSciences (Nasdaq:PCRX) reported second quarter 2026 total revenue of $192.4 million, up 6% year over year. GAAP net income was $4.7 million, or $0.12 per share, versus a $4.8 million loss a year ago. Non-GAAP net income was $29.5 million and adjusted EBITDA was $48.7 million.
EXPAREL net product sales were $147.8 million (+3%), ZILRETTA sales were $32.6 million (+4%), and iovera° sales were $6.8 million (+22%). Pacira closed the divestiture of its iovera° business to Zimmer Biomet, receiving $73.6 million at closing and eligibility for up to $140 million in total consideration.
According to Pacira, UnitedHealthcare now provides separate reimbursement for EXPAREL in outpatient settings. The company advanced its PCRX-201 gene therapy program into a scalable commercial manufacturing process and Part B enrollment of the Phase 2 ASCEND study. Pacira ended the quarter with $251.0 million in cash and updated 2026 total revenue guidance to $735–$760 million, adjusting for the iovera° sale, while reiterating EXPAREL sales and margin guidance.